Literature DB >> 27615057

Fibroblast growth factor 21 correlates with weight loss after vertical sleeve gastrectomy in adolescents.

Farooq H Khan1, Lindsey Shaw2, Wujuan Zhang3, Rosa Maria Salazar Gonzalez4, Sarah Mowery4, Melissa Oehrle3, Xueheng Zhao3, Todd Jenkins3, Kenneth D R Setchell3, Thomas H Inge2, Rohit Kohli5.   

Abstract

OBJECTIVE: Vertical sleeve gastrectomy (VSG) results in weight loss and increased bile acids (BA) and fibroblast growth factor 19 (FGF19) levels. FGF21 shares essential cofactors with FGF19, but its physiology early post-VSG has not been assessed.
METHODS: Ten adolescents (17.4 ± 0.5 years and BMI 51.5 ± 2.5 kg/m2 ) were enrolled. Fasting and postmeal (100 mL Ensure™) samples (0-120 min) were collected (pre-VSG [V1], 1 [V2], and 3 months [V3] post-VSG) for analysis of BA, FGF19, and FGF21.
RESULTS: Post-VSG subjects lost weight (V2 11.8 ± 0.8 kg; V3 21.9 ± 1.7 kg). BA and FGF19 increased by V2, 143.6% at 30 min and 74.9% at 90 min post-meal, respectively. BA hydrophobicity index also improved by V3, 21.1% at 30 min post-meal. Interestingly, fasting and 120-min post-meal FGF21 levels at V2 were increased by 135.7% and 253.9%, respectively, but then returned to baseline at V3. BA levels correlated with FGF21 at V2 (P = 0.003, r = 0.89), and body weight lost post-VSG correlated with FGF21 levels (V2; P = 0.012, R = 0.82).
CONCLUSIONS: Expected changes were seen in BA and FGF19 biology after VSG in adolescents, but novel changes were seen in correlation between the early postsurgical increase in FGF21 and weight loss, suggesting that FGF21 may play a role in energy balance postoperatively, and further investigation is warranted.
© 2016 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27615057      PMCID: PMC5846337          DOI: 10.1002/oby.21658

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  29 in total

1.  Effects of chemical modification of ursodeoxycholic acid on TGR5 activation.

Authors:  Yusuke Iguchi; Tomoko Nishimaki-Mogami; Masafumi Yamaguchi; Fumiteru Teraoka; Tetsuo Kaneko; Mizuho Une
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

2.  Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.

Authors:  Clarence Hale; Michelle M Chen; Shanaka Stanislaus; Narumol Chinookoswong; Todd Hager; Minghan Wang; Murielle M Véniant; Jing Xu
Journal:  Endocrinology       Date:  2011-11-08       Impact factor: 4.736

3.  Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids.

Authors:  G Mingrone; A DeGaetano; A V Greco; E Capristo; G Benedetti; M Castagneto; G Gasbarrini
Journal:  Diabetologia       Date:  1997-05       Impact factor: 10.122

4.  Obesity is a fibroblast growth factor 21 (FGF21)-resistant state.

Authors:  Ffolliott M Fisher; Patricia C Chui; Patrick J Antonellis; Holly A Bina; Alexei Kharitonenkov; Jeffrey S Flier; Eleftheria Maratos-Flier
Journal:  Diabetes       Date:  2010-08-03       Impact factor: 9.461

5.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.

Authors:  Mitsuhiro Watanabe; Sander M Houten; Li Wang; Antonio Moschetta; David J Mangelsdorf; Richard A Heyman; David D Moore; Johan Auwerx
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

6.  Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.

Authors:  M Mraz; M Bartlova; Z Lacinova; D Michalsky; M Kasalicky; D Haluzikova; M Matoulek; I Dostalova; V Humenanska; M Haluzik
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-11       Impact factor: 3.478

7.  Bile acids synthesis decreases after laparoscopic sleeve gastrectomy.

Authors:  Alex Escalona; Rodrigo Muñoz; Veronica Irribarra; Sandra Solari; Fidel Allende; Juan Francisco Miquel
Journal:  Surg Obes Relat Dis       Date:  2015-12-02       Impact factor: 4.734

8.  Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans.

Authors:  Xinmei Zhang; Dennis C Y Yeung; Michal Karpisek; David Stejskal; Zhi-Guang Zhou; Feng Liu; Rachel L C Wong; Wing-Sun Chow; Annette W K Tso; Karen S L Lam; Aimin Xu
Journal:  Diabetes       Date:  2008-02-05       Impact factor: 9.461

9.  The role of small heterodimer partner in nonalcoholic fatty liver disease improvement after sleeve gastrectomy in mice.

Authors:  Andriy Myronovych; Rosa-Maria Salazar-Gonzalez; Karen K Ryan; Lili Miles; Wujuan Zhang; Pinky Jha; Li Wang; Kenneth D R Setchell; Randy J Seeley; Rohit Kohli
Journal:  Obesity (Silver Spring)       Date:  2014-11       Impact factor: 5.002

10.  Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.

Authors:  Jing Xu; David J Lloyd; Clarence Hale; Shanaka Stanislaus; Michelle Chen; Glenn Sivits; Steven Vonderfecht; Randy Hecht; Yue-Sheng Li; Richard A Lindberg; Jin-Long Chen; Dae Young Jung; Zhiyou Zhang; Hwi-Jin Ko; Jason K Kim; Murielle M Véniant
Journal:  Diabetes       Date:  2008-10-07       Impact factor: 9.461

View more
  13 in total

1.  Increased glycine-amidated hyocholic acid correlates to improved early weight loss after sleeve gastrectomy.

Authors:  Tammy L Kindel; Crystal Krause; Melissa C Helm; Corrigan L McBride; Dmitry Oleynikov; Rhishikesh Thakare; Jawaher Alamoudi; Vishal Kothari; Yazen Alnouti; Rohit Kohli
Journal:  Surg Endosc       Date:  2017-08-04       Impact factor: 4.584

Review 2.  Targeting Islets: Metabolic Surgery Is More than a Bariatric Surgery.

Authors:  Xi Chen; Jingjing Zhang; Zhiguang Zhou
Journal:  Obes Surg       Date:  2019-09       Impact factor: 4.129

3.  Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.

Authors:  Laurie R Braun; Meghan N Feldpausch; Natalia Czerwonka; Martin Torriani; Steven K Grinspoon; Takara L Stanley
Journal:  Growth Horm IGF Res       Date:  2017-10-07       Impact factor: 2.372

4.  Increased Bile Acids and FGF19 After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Correlate with Improvement in Type 2 Diabetes in a Randomized Trial.

Authors:  Reza Nemati; Jun Lu; Dech Dokpuang; Michael Booth; Lindsay D Plank; Rinki Murphy
Journal:  Obes Surg       Date:  2018-09       Impact factor: 4.129

5.  Plasma FGF21 levels in obese patients undergoing energy-restricted diets or bariatric surgery: a marker of metabolic stress?

Authors:  A B Crujeiras; D Gomez-Arbelaez; M A Zulet; M C Carreira; I Sajoux; D de Luis; A I Castro; J Baltar; I Baamonde; A Sueiro; M Macias-Gonzalez; D Bellido; F J Tinahones; J A Martinez; F F Casanueva
Journal:  Int J Obes (Lond)       Date:  2017-06-07       Impact factor: 5.095

6.  Acute Changes of Bile Acids and FGF19 After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass.

Authors:  Yutao Chen; Jun Lu; Reza Nemati; Lindsay D Plank; Rinki Murphy
Journal:  Obes Surg       Date:  2019-11       Impact factor: 4.129

Review 7.  Bile acids and bariatric surgery.

Authors:  Vance L Albaugh; Babak Banan; Hana Ajouz; Naji N Abumrad; Charles R Flynn
Journal:  Mol Aspects Med       Date:  2017-04-17

Review 8.  ASMBS pediatric metabolic and bariatric surgery guidelines, 2018.

Authors:  Janey S A Pratt; Allen Browne; Nancy T Browne; Matias Bruzoni; Megan Cohen; Ashish Desai; Thomas Inge; Bradley C Linden; Samer G Mattar; Marc Michalsky; David Podkameni; Kirk W Reichard; Fatima Cody Stanford; Meg H Zeller; Jeffrey Zitsman
Journal:  Surg Obes Relat Dis       Date:  2018-03-23       Impact factor: 4.734

9.  Postprandial Uridine Physiology Is Altered by Obesity.

Authors:  Rohit Kohli; Jashdeep Bhattacharjee; Thomas H Inge
Journal:  Gastroenterology       Date:  2018-08-22       Impact factor: 22.682

10.  Effect of Weight Loss by Low-Calorie Diet on Cardiovascular Health in Type 2 Diabetes: An Interventional Cohort Study.

Authors:  Shaden Melhem; Sarah Steven; Roy Taylor; Ahmad Al-Mrabeh
Journal:  Nutrients       Date:  2021-04-26       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.